(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.55%) $2.05
(0.01%) $2 347.50
(-0.35%) $27.44
(4.11%) $960.00
(-0.22%) $0.933
(-0.34%) $10.99
(-0.54%) $0.796
(1.55%) $93.30
Quarter results today
(bmo 2024-04-29)
Expected move: +/- 4.04%
0.58% INR 507.05
Live Chart Being Loaded With Signals
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...
Stats | |
---|---|
Dagens volum | 122 635 |
Gjennomsnittsvolum | 217 350 |
Markedsverdi | 46.62B |
EPS | INR0 ( 2024-04-13 ) |
Neste inntjeningsdato | ( INR0 ) 2024-07-18 |
Last Dividend | INR1.000 ( 2023-02-08 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 25.92 |
ATR14 | INR0.783 (0.15%) |
Volum Korrelasjon
Aarti Drugs Limited Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BBL.NS | 0.955 |
RBLBANK.NS | 0.954 |
AIRAN.NS | 0.949 |
PGHH.NS | 0.944 |
KELLTONTEC.NS | 0.94 |
HPL.NS | 0.94 |
PREMEXPLN.NS | 0.939 |
SJVN.NS | 0.938 |
TWL.NS | 0.936 |
POLYCAB.NS | 0.934 |
10 Mest negative korrelasjoner | |
---|---|
LTGILTBEES.NS | -0.947 |
SINTEX.NS | -0.924 |
RAJRILTD.NS | -0.922 |
BOHRAIND.NS | -0.92 |
RAJVIR.NS | -0.911 |
BGLOBAL.NS | -0.906 |
IRISDOREME.NS | -0.906 |
OMAXE.NS | -0.905 |
JPINFRATEC.NS | -0.903 |
SRPL.NS | -0.901 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Aarti Drugs Limited Korrelasjon - Valuta/Råvare
Aarti Drugs Limited Økonomi
Annual | 2022 |
Omsetning: | INR27.16B |
Bruttogevinst: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Omsetning: | INR27.16B |
Bruttogevinst: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
FY | 2022 |
Omsetning: | INR24.89B |
Bruttogevinst: | INR5.04B (20.24 %) |
EPS: | INR22.12 |
FY | 2021 |
Omsetning: | INR21.55B |
Bruttogevinst: | INR6.00B (27.86 %) |
EPS: | INR30.09 |
Financial Reports:
No articles found.
Aarti Drugs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2003-11-13 |
Last Dividend | INR1.000 | 2023-02-08 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 32 | -- |
Total Paid Out | INR15.88 | -- |
Avg. Dividend % Per Year | 0.23% | -- |
Score | 2.13 | -- |
Div. Sustainability Score | 4.77 | |
Div.Growth Potential Score | 3.36 | |
Div. Directional Score | 4.06 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.250 | 0.18% |
2019 | INR0.250 | 0.17% |
2020 | INR3.00 | 2.03% |
2021 | INR0 | 0.00% |
2022 | INR1.000 | 0.18% |
2023 | INR1.000 | 0.22% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ROUTE.NS | Dividend Junior | 2023-09-06 | Semi-Annually | 4 | 0.38% | |
LICHSGFIN.NS | Dividend Junior | 2023-08-18 | Annually | 23 | 1.85% | |
GANDHITUBE.NS | Dividend Junior | 2023-07-28 | Annually | 17 | 1.82% | |
APOLSINHOT.NS | Dividend Junior | 2023-09-22 | Annually | 10 | 0.11% | |
TDPOWERSYS.NS | Dividend Junior | 2023-08-02 | Annually | 13 | 0.31% | |
OLECTRA.NS | Dividend Junior | 2023-09-21 | Sporadic | 23 | 0.03% | |
INTENTECH.NS | Dividend Junior | 2023-09-21 | Annually | 6 | 0.44% | |
COROMANDEL.NS | Dividend Knight | 2023-07-13 | Annually | 19 | 1.02% | |
SHALBY.NS | Dividend Junior | 2023-08-08 | Annually | 6 | 0.51% | |
MANALIPETC.NS | Dividend Junior | 2023-09-15 | Annually | 18 | 1.50% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0680 | 1.500 | 8.64 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.150 | 1.500 | 9.44 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 8.41 | 1.000 | 8.00 | 8.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 4.52 | 9.04 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.322 | 1.000 | 7.96 | 7.96 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.105 | 1.000 | 9.91 | 9.91 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 25.92 | 1.000 | 7.48 | 0 | [1 - 100] |
returnOnEquityTTM | 0.150 | 2.50 | 9.64 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 9.04 | [0 - 30] |
dividendYielPercentageTTM | 0.197 | 1.500 | 5.08 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.373 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0380 | 1.000 | -1.550 | 0 | [0.1 - 0.5] |
Total Score | 3.36 |
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.